NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)?Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive?Did you lose money in your investment in Biogen Inc.?Do you want to discuss your rights? Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and Febru ...

Investors can contact the law firm at no cost to learn more about recovering their losses. LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Biogen Inc. (“Biogen”) (NASDAQ: BIIB) investors who suffered substantial losses to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can pro ...

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. (“Biogen”) (NASDAQ: BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Biogen’s ...

Upcoming community events will inform plans to create more equitable flying experiences for passengers with reduced mobility CAMBRIDGE, Mass. and ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Delta Flight Products (DFP), a wholly-owned subsidiary of Delta Air Lines established to create aircraft interior solutions to airlines around the world, announced that the companies will collaborate to inform future enhancements to the air travel journey for passengers with reduced mobility. ...

Core Viewpoint - Biogen Inc. and Delta Flight Products are collaborating to enhance air travel accessibility for passengers with reduced mobility, particularly those using wheelchairs, aiming to create a more equitable flying experience [1][2]. Group 1: Collaboration Details - The partnership will involve community events to gather insights from individuals with rare disease mobility restrictions, focusing on their travel experiences and needs [2]. - The first event will take place at the Cure SMA's 2024 Annual SMA Conference from June 6-9, 2024, in Austin, Texas, where feedback will be collected and shared publicly [2][3]. Group 2: Innovations and Products - Delta Flight Products has developed a prototype airplane seat that allows passengers to remain in their own wheelchairs during the flight, addressing a significant gap in travel accessibility [3][4]. - The innovative seat design includes features for comfort and safety, such as adjustable headrests and tray tables, and has received the APEX 2024 Innovation Award for Best Cabin [4]. Group 3: Company Backgrounds - Biogen is a leading biotechnology company focused on innovative treatments for patients with neuromuscular diseases, emphasizing independence and accessibility [5]. - Delta Flight Products specializes in aircraft interior solutions, providing engineering and manufacturing services to enhance airline cabin designs [8].

NEW YORK, May 30, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen's third rare disease therapy to be approved in the EU, demonstrating the company's commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...

Jeito Capital announces the acquisition by Merck & Co (NYSE:MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress achieved with Restoret™, EyeBio's novel late-phase candidate for diabetic macular edema, as well as a preclinical pipeline targeting retinal diseases - Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024 The acquisition by Merck & Co (NYSE:MRK), a global biopharmaceutical c ...